The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease

Internal Medicine

Volumn 55, Issue 3, 2016, Pages 223-229

  Furutate, Ryuko ^a   Ishii, Takeo ^a   Motegi, Takashi ^a   Hattori, Kumiko ^a   Kusunoki, Yuji ^a   Gemma, Akihiko ^a   Kida, Kozui ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

BODE index; COPD; Exacerbation; Inflammation; Neutrophil to lymphocyte ratio

Indexed keywords

C REACTIVE PROTEIN;

6 MINUTE WALK DISTANCE; AGED; AIRWAY OBSTRUCTION; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; EXERCISE; FAT FREE MASS INDEX; FAT MASS INDEX; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERVIEW; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; NEUTROPHIL LYMPHOCYTE RATIO; PERCENTAGE OF LOW ATTENUATION AREA; SCORING SYSTEM; SMOKING; BLOOD; CROSS-SECTIONAL STUDY; DISEASE COURSE; EPIDEMIOLOGY; EXERCISE TEST; EXERCISE TOLERANCE; IMMUNOLOGY; INFLAMMATION; JAPAN; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; NEUTROPHIL; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; INFLAMMATION; JAPAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84956691269     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5772     Document Type: Article

References (45)

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365, 2013.
2. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11: 122, 2010.
3. Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clini cal perspective from the study team. Am J Respir Crit Care Med 189: 1022-1030, 2014.
4. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182: 598-604, 2010.
5. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-773, 2007.
6. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359: 2355-2365, 2008.
7. Nathan C. Points of control in inflammation. Nature 420: 846-852, 2002.
8. Ishii T, Kida K. Predictors of chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 20: 138-145, 2014.
9. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519-553, 2011.
10. Borregaard N. Neutrophils, from marrow to microbes. Immunity 33: 657-670, 2010.
11. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173-182, 2006.
12. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378: 1015-1026, 2011.
13. Zahorec R. Ratio of neutrophil to lymphocyte counts: rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102: 5-14, 2001.
14. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 97: 993-996, 2006.
15. Arbel Y, Finkelstein A, Halkin A, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 225: 456-460, 2012.
16. Günay E, Sarinç Ula_li S, Akar O, et al. Neutrophil-tolymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation 37: 374-380, 2014.
17. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350: 1005-1101, 2004.
18. Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 128: 3810-3816, 2005.
19. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 131: 696-704, 2007.
20. Marin JM, Carrizo SJ, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 103: 373-378, 2009.
21. Motegi T, Jones RC, Ishii T, et al. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis 8: 259-271, 2013.
22. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152: 1107-1136, 1995.
23. Clinical Pulmonary Functions Committee of the Japanese Respiratory Society. The predicted values of spirometry and arterial blood gas analysis in Japanese. Nihon Kokyuki Gakkai Zasshi (J Jpn Respir Soc) 39: Appendix 1-17, 2001 (in Japanese).
24. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 93: 580-586, 1988.
25. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 166: 111-117, 2002.
26. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 162 (3 Pt 1): 1102-1108, 2000.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987.
28. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 66: 197-204, 2011.
29. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130-1139, 2005.
30. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31: 1334-1356, 2008.
31. Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 61: 196-201, 2006.
32. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 48: 531-539, 2013.
33. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653, 2004.
34. Cockayne DA, Cheng DT, Waschki B, et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 7: e38629, 2012.
35. Tanriverdi H, Örnek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/ lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr 127: 756-763, 2015.
36. de Jager CP, Wever PC, Gemen EF, et al. The neutrophillymphocyte count ratio in patients with community-acquired pneumonia. PLoS One 7: e46561, 2012.
37. de Jager CP, van Wijil PT, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophillymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 14: R192, 2010.
38. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185, 2009.
39. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 1: 73-83, 2013.
40. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187: 728-735, 2013.
41. Van Remoortel H, Hornikx M, Langer D, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 189: 30-38, 2014.
42. Sørensen AK, Holmgaard DB, Mygind LM, Johansen J, Pedersen C. Neutrophil-to lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality: a cohort study. J Inflamm 12: 20, 2015.
43. Jilma B, Hergovich N, Stohlawetz P, Eichler HG, Bauer P, Wagner OF. Circadian variation of granulocyte colony stimulating factor levels in man. Br J Haematol 106: 368-370, 1999.
44. Cermakian N, Lange T, Golombek D, et al. Crosstalk between the circadian clock circuitry and the immune system. Chronobiology Int 30: 870-888, 2013.
45. Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymphocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost 19: 579, 2013.